Ascentage Pharma Group International (NASDAQ:AAPG) Announces Quarterly Earnings Results

Ascentage Pharma Group International (NASDAQ:AAPG) posted its quarterly earnings results on Wednesday. The company reported ($0.65) EPS for the quarter, reports. The company had revenue of $22.24 million during the quarter.

Ascentage Pharma Group International Price Performance

Shares of AAPG opened at $17.32 on Friday. The stock’s 50-day moving average price is $18.21 and its two-hundred day moving average price is $21.23. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. Ascentage Pharma Group International has a 12 month low of $16.36 and a 12 month high of $48.45.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG lifted its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth $383,000.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AAPG. B. Riley Financial began coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.